Recent News

Otonomy Achieves Patient Enrollment Target in Phase 2b Clinical Trial of OTO-104 in Meniere’s Disease

SAN DIEGO, Dec. 1, 2014 (GLOBE NEWSWIRE) Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that the company has achieved target enrollment in its Phase 2b clinical trial of OTO-104 in patients with Ménière’s disease. (more…)

ZS Pharma Announces Publication of Results From Phase 3 Study of ZS-9 in Patients With Hyperkalemia in the New England Journal of Medicine

ZS-9 Normalizes 98 Percent of Patients Within 48 Hours and a High Proportion of Patients Who Continued on ZS-9 Maintained Normokalemia

COPPELL, Texas, Nov. 21, 2014 (GLOBE NEWSWIRE)ZS Pharma (Nasdaq:ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced the publication of previously unreleased detailed results from the ZS003 study in the New England Journal of Medicine (NEJM). (more…)

ZS Pharma Presents Positive Results from HARMONIZE (ZS004), a Second Phase 3 Clinical Trial of ZS-9 in Patients with Hyperkalemia, at the American Heart Association Scientific Meeting and Announces Simultaneous Publication of Results in JAMA

Coppell, Texas – November 17, 2014 – ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions. HARMONIZE is the second positive Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate) for the treatment of hyperkalemia, a life threatening condition characterized by abnormally high concentrations of potassium in the blood (serum K+ ≥5.1 mEq/L). In addition to the presentation, the study results were simultaneously published today in The Journal of the American Medical Association (JAMA). (more…)

Kindred Announces Definitive Agreement to Acquire Centerre Healthcare

Creating One of Nation’s Largest Networks of Inpatient Rehabilitation Hospitals and Significantly Expanding Kindred’s Continuum of Services

Kindred to Establish New Growth Platform, Kindred Hospital Rehabilitation Services, Upon Closing of the Transaction

November 12, 2014 08:00 AM Eastern Standard Time

LOUISVILLE, Ky.–(BUSINESS WIRE)–Kindred Healthcare, Inc. (“Kindred” or the “Company”) (NYSE:KND), the nation’s largest provider of integrated post-acute care and rehabilitation, today announced that it has signed a definitive merger agreement to acquire Centerre Healthcare Corporation (“Centerre”), a national company dedicated to operating Inpatient Rehabilitation Hospitals, for a purchase price of approximately $195 million in cash. Read more

Source:  Business Wire

Otonomy Obtains Rights to Gacyclidine Data From Ipsen to Support Development of OTO-311 as a Treatment for Tinnitus

SAN DIEGO and PARIS, Nov. 6, 2014 (GLOBE NEWSWIRE) — Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, and Ipsen (Euronext:IPN) (ADR:IPSEY), a global specialty-driven pharmaceutical company, today announced that they have entered into an exclusive licensing agreement enabling Otonomy to utilize Ipsen’s gacyclidine data in the development and registration of OTO-311. OTO-311 is Otonomy’s sustained-exposure formulation of gacyclidine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, in development for the treatment of tinnitus. (more…)

ZS Pharma Announces Multiple Presentations from ZS003, a Phase 3 Trial of ZS-9, at the American Society of Nephrology Annual Meeting

Coppell, Texas – October 30, 2014ZS Pharma (Nasdaq: ZSPH), a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that data from ZS003, a pivotal Phase 3 trial of ZS-9 (sodium zirconium cyclosilicate), its investigational treatment for hyperkalemia, will be presented in multiple presentations at the American Society of Nephrology (ASN) Annual Meeting in Philadelphia, Pa. which is taking place from November 11 to 16, 2014. (more…)

Otonomy Appoints Anthony J. Yost Chief Commercial Officer

SAN DIEGO, Oct. 21, 2014 (GLOBE NEWSWIRE) Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Anthony J. Yost as chief commercial officer. (more…)

Otonomy Enrolls First Meniere’s Disease Patients in OTO-104 Multiple-Dose Safety Study

SAN DIEGO, Oct. 9, 2014 (GLOBE NEWSWIRE) Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the enrollment of the first patients in a multiple-dose safety study of OTO-104 initiated in the United Kingdom (U.K.) in patients with Ménière’s disease. (more…)

Otonomy Added To Russell 2000(R) Index

SAN DIEGO, Oct. 1, 2014 (GLOBE NEWSWIRE) Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the inner and middle ear, today announced that the company was added to the Russell 2000® Index as part of Russell Investments’ quarterly addition of select initial public offering (IPO) companies. (more…)

Allakos Inc. Raises Additional $10 Million to Expand its Portfolio and Fund Development of an Additional Antibody for Allergic and Inflammatory Diseases

Chief Medical Officer Appointed to Advance Growing Portfolio; Series A Extension Earmarked for Second Product Candidate Preclinical Development

San Carlos, CA – September 30, 2014 Allakos Inc. announced today that it has secured an additional $10 million investment from current investors to fund development of an additional therapeutic antibody. (more…)